# Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

> **NCT00126607** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- High-grade Salivary Gland Mucoepidermoid Carcinoma
- Recurrent Salivary Gland Cancer
- Salivary Gland Acinic Cell Tumor
- Salivary Gland Adenocarcinoma
- Salivary Gland Poorly Differentiated Carcinoma
- Stage IVA Salivary Gland Cancer
- Stage IVB Salivary Gland Cancer
- Stage IVC Salivary Gland Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00126607
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Poor accrual.
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126607, "Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00126607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*